COSNALAP: Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Study Details
Study Description
Brief Summary
The purpose of this study was to investigate the clinical outcomes of patients with locally advanced pancreatic cancer (LA-PC) who underwent surgery after neoadjuvant chemotherapy (NACT) at Asan Medical Center's Department of Hepato-Biliary-Pancreatic Surgery from 2017 to 2020.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Pancreatic cancer (PC) has a very low survival rate. Most PC patients have non-specific symptoms that are advanced enough to be contraindications for surgical treatment; therefore, surgery is often impossible by the time PC is diagnosed. According to the NCCN guidelines, PCs with no metastases can be divided into resectable, borderline resectable , and locally advanced cases. Patients with borderline resectable PC (BR-PC) and locally advanced PC (LA-PC) currently receive multimodal therapy before surgery. The goal of these neoadjuvant treatments, including chemotherapy and radiation therapy, is to ultimately reduce local recurrence after surgery in patients with BR-PC and further improve their survival time. Additionally, several recent studies have reported results on the prognosis when surgery is performed after neoadjuvant chemotherapy (NACT) in patients with LA-PC. In the patients with LA-PC, surgery technically difficult because of major vascular invasion before NACT. Therefore, this study investigated the clinical outcomes of patients with LA-PC who underwent surgery after NACT. Additionally, the investigators evaluated factors affecting the prognosis related to survival after surgery in patients with LA-PC.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| locally advanced pancreatic cancer Locally advanced pancreatic cancer (LA-PC) is classified according to the National Comprehansive Cancer Networks (NCCN) guidelines. Patients with the above conditions underwent surgery after neoadjuvant chemotherapy. |
Procedure: surgery after neoadjuvant chemotherapy
surgery after neoadjuvant chemotherapy
|
| borderline resectable pancreatic cancer Borderline resectable pancreatic cancer (BR-PC) is classified according to the NCCN guidelines. Patients with the above conditions underwent surgery after neoadjuvant chemotherapy. |
Procedure: surgery after neoadjuvant chemotherapy
surgery after neoadjuvant chemotherapy
|
| resectable pancreatic cancer Resectable pancreatic cancer (PC) is classified according to the NCCN guidelines. There are no arterial and venous contact with tumor Patients with the above conditions underwent upfront surgery |
Outcome Measures
Primary Outcome Measures
- oncologic outcome [3 - 5 years after surgery]
overall survival and recurrence free survival according to the groups
Eligibility Criteria
Criteria
Inclusion Criteria:
- The study population consists of patients who underwent pancreatectomy for pancreatic adenocarcinoma between January 2017 and December 2020
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Asan medical center | Seoul | Korea, Republic of | 05505 |
Sponsors and Collaborators
- Asan Medical Center
Investigators
- Principal Investigator: Song Cheol Kim, MD. PhD, Asan Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2016-0902